24 results about "Genus Echinococcus" patented technology

The invention relates to the technical field of tapeworm identification, and provides a kit for identifying five target tapeworms by using specific primers and application of the kit. All mainstream genotypes of genes of Echinococcus granulosus, Echinococcus multilocularis, Taenia vesicula, Taenia multiceps and Taenia canis are compared, and a primer pair capable of universally detecting nucleic acids of five tapeworms is obtained by taking conserved regions of the genes as diagnostic targets. The rapid detection of the five pathogens is realized by combining with a digoxin-labeled nucleic acid lateral chromatography test paper. A product obtained by isothermal amplification is detected by a nucleic acid detection test strip and then is directly observed by eyes, and the result is interpreted within 15-20 minutes, so that the operation is simple and convenient. The method provided by the invention has wide application prospects in the aspects of large-scale screening and detection of whether dogs are infected with echinococcus granulosus, echinococcus multilocularis, taenia vesicula, taenia multiceps and tapestoma dogs or not in pasturing areas, especially in areas with epidemic echinococcosis, and evaluation of the insect expelling effect of the dogs fed with praziquantel on the tapeworms.

The invention discloses application of lenvatinib (E7080) in treatment of alveolar echinococcosis, and belongs to the field of biomedicine. The technical problem to be solved by the invention is how to treat and / or prevent alveolar echinococcosis. It is found that lenvatinib (E7080) can cause falling of a head hook of an original head section of echinococcus multilocularis, shrinkage of a body section, damage to structures such as a suction cup and microvillus, and the in-vivo pathogenicity is remarkably reduced; the structure of the vesicles in the middle polyester period can be destroyed, so that the hair growth layers of the vesicles shrink and are separated from the cuticle. It is shown that lenvatinib (E7080) has a good killing effect on echinococcus multilocularis and can be used for preparing the medicine for treating the alveolar echinococcosis.

The invention discloses an echinococcus multilocularis monoclonal antibody and a fluorescent microsphere immunochromatography detection test strip, and relates to the technical field of monoclonal antibodies. The echinococcus multilocularis monoclonal antibody is an echinococcus multilocularis monoclonal antibody 13H11F4, the amino acid sequence of a heavy chain of the echinococcus multilocularis monoclonal antibody is shown as SEQ ID NO.1, and the amino acid sequence of a light chain of the echinococcus multilocularis monoclonal antibody is shown as SEQ ID NO.2. The monoclonal antibody 13H11F4 of the echinococcus multilocularis can be combined with other monoclonal antibodies of the echinococcus multilocularis, so that the echinococcus multilocularis can be detected by a double-antibody sandwich method. The fluorescent microsphere immunochromatography test strip prepared from 13H11F4 and other monoclonal antibodies of other echinococcosis multilocularis is used for medical detection of echinococcosis multilocularis, has the advantages of high sensitivity, short reaction time, strong anti-interference capability and accurate and reliable detection result, and has wide clinical application value.

The invention relates to the technical field of molecular biology, and discloses a primer probe set for species identification of echinococcus granulosus, and the primer probe set comprises a first primer probe set for targeting echinococcus granulosus, a second primer probe set for targeting echinococcus multilocularis and / or a third primer probe set for targeting echinococcus stone. According to the primer probe group, synchronous, rapid and high-specificity identification and detection of three kinds of echinococcus, namely echinococcus granulosus (Eg), echinococcus multilocularis (Em) and echinococcus stone (Es), are realized. When the primer probe group is used for identifying and detecting the three kinds of echinococcus, the detection sensitivity reaches 200 copies / mL, and the positive coincidence rate reaches 100%. The primer probe group realizes synchronous and accurate identification of echinococcus species, and has a wide application prospect in molecular epidemiological investigation and port quarantine.

The invention discloses an echinococcus multilocularis monoclonal antibody and a fluorescent microsphere immunochromatography detection test strip, and relates to the technical field of monoclonal antibodies. The echinococcus multilocularis monoclonal antibody comprises an echinococcus multilocularis monoclonal antibody 20B7D9 and an echinococcus multilocularis monoclonal antibody 18F11G9, and the echinococcus multilocularis monoclonal antibody 20B7D9 and the echinococcus The echinococcus multilocularis monoclonal antibody 20B7D9 can be combined with the echinococcus multilocularis monoclonal antibody 18F11G9, so that the echinococcus multilocularis can be detected by a double-antibody sandwich method. The fluorescent microsphere immunochromatography test strip prepared from the 20B7D9 and the echinococcosis multilocularis monoclonal antibody 18F11G9 is used for medical detection of echinococcosis multilocularis, has the advantages of high sensitivity, short reaction time, strong anti-interference capability and accurate and reliable detection result, and has wide clinical application value.

This invention discloses a bivalent subunit vaccine against Echinococcus granulosus and Echinococcus cantonensis, and its preparation method. The bivalent subunit vaccine comprises the immunogen dEG95 / dEC95 antigen protein and a pharmaceutically acceptable carrier. The amino acid sequence of the dEG95 protein is shown in SEQ ID No. 1, and the amino acid sequence of the dEC95 protein is shown in SEQ ID No. 2. Currently, there are no vaccines that simultaneously protect against Echinococcus granulosus and Echinococcus cantonensis infection. This invention uses the dEG95-dEC95 heterodimeric protein as the antigen, and the prepared bivalent subunit vaccine against both Echinococcus granulosus and Echinococcus cantonensis has low production cost and a simple production process. It can simultaneously prevent infection by both Echinococcus granulosus and Echinococcus cantonensis, and has many advantages such as safety, high efficiency, low cost, and high antigen purity.

The present invention discloses the use of the fatty acid amide hydrolase inhibitor PF-3845 as a drug for the preparation of a drug for treating alveolar echinococcosis. The present invention finds that the fatty acid amide hydrolase inhibitor PF-3845 can destroy the head hook, sucker, microvilli and other structures of the protoscolecus of Echinococcus multilocularis, causing the protoscolecus to lyse and die, and can also destroy the structure of the vesicles in the tapeworm stage, causing the vesicles to collapse. This shows that the fatty acid amide hydrolase inhibitor PF-3845 has a good killing effect on Echinococcus multilocularis and can be used as an alternative to albendazole to treat echinococcosis, with good application prospects.

This invention discloses a multilocular echinococcosis larva. In Preparation method of -6B protein and its application in the preparation of anti-host inflammatory agents. Through protein structure modeling and molecular docking technology, the preparation method was confirmed. In -6B can bind with high affinity to a key subunit of the host 26S proteasome, affecting the assembly of the proteasome in the host and thus interfering with the activity of the NF-κB signaling pathway, thereby regulating the host inflammatory response. Animal experiments have shown that recombinant... In -6B intervention significantly alleviated colonic damage in mice with inflammatory bowel disease, regulated the expression levels of pro-inflammatory and anti-inflammatory factors, and improved the survival rate of septic mice, with no obvious toxic side effects observed. This invention opens up a new pathway for developing anti-inflammatory agents using natural molecules that interact with the parasite's immune system, and provides a novel mechanism of action and biosafety for anti-host inflammatory biological agents, showing great potential for application in the prevention and treatment of inflammatory diseases in humans and livestock.

The invention provides application of vitamin D (VD) in preparation of a medicine for preventing and / or treating echinococcosis infection, and belongs to the technical field of biological medicine. According to the application of the VD in preparation of the medicine for preventing and / or treating the echinococcosis infection, the concentration of the VD in the medicine is not lower than 1000 IU / kg or 100 IU / mL. According to the present invention, the high dose (10000 IU / kg) VD drug delivery group can significantly reduce the weight of the echinococcosis cyst in the mouse, such that the high dose VD can inhibit the growth of parasites through the immune regulation effect, and can regulate the lactobacillus level in the mouse intestinal flora so as to improve the immune response and reduce the survival and the proliferation of the echinococcosis multilocularis in the mouse body; the invention provides a new thought and strategy for the treatment of the echinococcosis.

The invention discloses a synthetic antibacterial peptide and application thereof in resisting echinococcus multilocularis, and belongs to the technical field of biology. The antibacterial peptide is an antibacterial peptide C16KGGK-NH2, the structural formula of the antibacterial peptide is C16-Lys-Gly-Gly-Lys-NH2, the antibacterial peptide contains four amino acids which are lysine, glycine, glycine and lysine in sequence, and the carboxyl of the last lysine is amidated. The antibacterial peptide provided by the invention has low hemolytic activity, low toxicity to normal cells and remarkable antigen cephalosporium activity, and shows good biological safety and potential application value.

This invention discloses a multiplex PCR primer combination, kit, and detection method for detecting Echinococcus granulosus. The multiplex PCR primer combination includes a second primer combination and a third primer combination: the second primer combination consists of upstream and downstream primers specific to Echinococcus multilocularis, with sequences shown in SEQ ID NO. 3 and SEQ ID NO. 4, respectively; the third primer combination consists of upstream and downstream primers specific to Echinococcus shiquensis, with sequences shown in SEQ ID NO. 5 and SEQ ID NO. 6, respectively. This invention saves more time than conventional PCR, is more cost-effective than quantitative real-time PCR, and has lower requirements for operators and equipment, showing great promise for the detection and control of echinococcosis.

This invention provides an animal model of hepatic echinococcosis caused by *Echinococcus multilocularis*, its construction method, and its applications. The construction method mainly includes preserving the protoscolex, extracting the protoscolex of *Echinococcus multilocularis*, and injecting the preserved protoscolex into C57BL / 6N mice. The resulting mouse model can be used to observe the infection and development of hepatic echinococcosis, and to screen and / or evaluate hepatic echinococcosis drugs. The advantages of this invention are that it explores the growth pattern of *Echinococcus multilocularis* and its impact on the hepatic vascular system from a novel perspective. Furthermore, addressing the problems of complex and high-risk traditional modeling methods, it proposes an optimized liver-targeted inoculation pathway and establishes a standardized pathogen treatment process, ensuring infection success rate and animal survival rate while reducing experimental interference factors.

The invention discloses an application of CA170 in preparation of a medicine for treating echinococcus multilocularis, and aims to realize effective treatment on echinococcus multilocularis infection. C57 / 6J mice infected by hepatic portal veins for 40 days through alveolar coccosis serve as research objects, CA-170 micromolecules are orally administrated, the dosage of CA-170 in the medicine is not lower than 10 mg / kg, the CA-170 is treated once every three days for one month, and the drug effect of CA-170 on protoscolex cystic development and focus growth in the bodies of the echinococcus multilocularis infected mice is detected. Results show that compared with a solvent control group, in-vivo focuses of mice in a CA-170 treatment group are reduced, and the number and the weight of echinococcosis cysts are remarkably reduced, indicating that CA170 shows a good effect in the aspect of resisting echinococcosis multilocularis infection, and can reduce the proportion of MDSC caused by the infection and relieve liver injury caused by the infection. According to the application scheme provided by the invention, technical support is provided for efficiently preventing and treating the echinococcosis multilocularis, and a foundation is laid for clinical treatment of the CA-170 on the echinococcosis multilocularis.

The invention discloses an antibacterial peptide for preventing and treating echinococcosis multilocularis and application of the antibacterial peptide, and belongs to the technical field of biology. The antibacterial peptide is an antibacterial peptide C16EGGE-NH2, the structural formula of the antibacterial peptide is C16-Glu-Gly-Gly-Glu-NH2, the antibacterial peptide contains four amino acids, namely glutamic acid, glycine, glycine and glutamic acid in sequence, and the carboxyl of the last glutamic acid is amidated. Although the antibacterial peptide C16EGGE-NH2 provided by the invention has a remarkable destructive effect on protoscolex multilocularis, the toxicity to normal cells is relatively low, and the antibacterial peptide C16EGGE-NH2 has selective killing ability and shows good biological safety and potential application value.

The invention discloses an echinococcus multilocularis monoclonal antibody and a fluorescent microsphere immunochromatography detection test strip, and relates to the technical field of monoclonal antibodies. The echinococcus multilocularis monoclonal antibody is an echinococcus multilocularis monoclonal antibody 2G7C3, the amino acid sequence of a heavy chain of the echinococcus multilocularis monoclonal antibody 2G7C3 is shown as SEQ ID NO.1, and the amino acid sequence of a light chain of the echinococcus multilocularis monoclonal antibody 2G7C3 is shown as SEQ ID The echinococcosis multilocularis monoclonal antibody 2G7C3 can be combined with other monoclonal antibodies of echinococcosis multilocularis, so that the echinococcosis multilocularis can be detected by a double-antibody sandwich method. The fluorescent microsphere immunochromatography test strip prepared from 2G7C3 and other monoclonal antibodies of other echinococcosis multilocularis is used for medical detection of echinococcosis multilocularis, has the advantages of high sensitivity, short reaction time, strong anti-interference capability and accurate and reliable detection result, and has wide clinical application value.

The invention discloses a rapid detection method for echinococcus multilocularis based on RPA-CRISPR / Cas, and belongs to the technical field of molecular diagnosis. The method comprises the following steps: extracting DNA of a sample to be detected; the specific primers are used for RPA isothermal amplification, a reaction system comprises a buffer solution, upstream and downstream primers, RPA enzyme, magnesium acetate and template DNA, and reaction is carried out at 39 DEG C for 20 minutes; and mixing the amplification product with Cas12a protein, sgRNA and a fluorescence report probe, carrying out CRISPR / Cas reaction at 37 DEG C for 30 minutes, and judging the result through a real-time fluorescence signal. Constant-temperature rapid amplification is achieved through RPA, high-sensitivity and high-specificity detection of echinococcus multilocularis can be achieved under the site condition by combining high-specificity recognition and cleavage activity of CRISPR / Cas12a, the sensitivity reaches the single-site copy number, operation is easy and convenient, complex instruments are not needed, and the method is suitable for primary medical treatment and site quarantine.

The invention relates to a nano antibody for resisting an echinococcus multilocularis antigen EMY162 as well as a screening method and application of the nano antibody, and belongs to the technical field of biological medicines. The invention provides a nano antibody for resisting an echinococcus multilocularis antigen EMY162. The amino acid sequence of the nano antibody is as shown in SEQ ID NO. 1 or SEQ ID NO. 3. The nano antibody disclosed by the invention has the characteristics of small molecular weight, short half-life period, low immunogenicity, strong antigen binding capacity, good tissue penetrability and high uniformity, safety and stability, and can show very high affinity activity on Echinococcus multilocularis EMY162 antigen protein.

The invention relates to a molecular marker primer, a kit and a method for rapidly identifying Echinococcus multilocularis genes. The molecular marker primer for rapidly identifying the Echinococcus multilocularis gene comprises a forward primer EM Primer F, a reverse primer EM Primer F, a reverse primer EM Primer F, a reverse primer EM Primer F, a reverse primer EM Primer F, a reverse primer EM Primer F, a reverse primer EM Primer F, a reverse primer EM Primer F and a reverse primer EM Primer F, the sequence of the reverse primer EM Primer R is TTATGCCTTCCTCAGTAAT, and the sequence of the reverse primer EM Primer R is TTATGCCTTCCTCAGTAAT. According to the molecular marker primer, the kit and the method for rapidly identifying the Echinococcus multilocularis gene, the molecular marker primer specially targets a highly conserved region of the Echinococcus multilocularis mitochondrion cob gene, and a target band near 500bp can be specifically detected from an excrement or tissue sample through combination of PCR amplification and agarose gel electrophoresis; the rapid and accurate identification of the echinococcus multilocularis is realized; by utilizing the characteristics of high copy number and low variation rate of the mitochondrial gene, the problems of low sensitivity and poor specificity of the traditional method are solved, the method is particularly suitable for early diagnosis, large-scale screening and environmental monitoring, and an efficient technical means is provided for prevention and control of echinococcosis.

This invention relates to the field of pharmaceutical biotechnology, and provides a polynucleotide sponge molecule targeting emu-miR-2c-3p. The core sequence of emu-miR-2c-3p is shown in SEQ ID NO.1. The polynucleotide sponge molecule is characterized by comprising four tandemly arranged binding units that are specifically reverse complementary to the sequence shown in SEQ ID NO.1, with the sequence of a single binding unit shown in SEQ ID NO.2. Adjacent binding units are connected by TATAC, ACATC, and TCTTCA spacer sequences in sequence, and the sequence of the polynucleotide sponge molecule is shown in SEQ ID NO.3. To achieve the purpose of interfering with or knocking down emu-miR-2c-3p, this invention provides a polynucleotide sponge molecule capable of specifically adsorbing emu-miR-2c-3p derived from *Echinococcus multilocularis*. Building upon this foundation, a recombinant adeno-associated virus rAAV2 / 9-TBG-emu-miR-2c-3p-sponge-LUC, driven by a liver-specific TBG promoter, was further constructed. This virus can efficiently target and deliver sponge molecules to the host liver, interfering with or knocking down the expression of emu-miR-2c-3p, thereby disrupting the vascularized microenvironment on which the parasite depends for growth, and achieving the goal of inhibiting or treating the growth of Echinococcus multilocularis.

The invention discloses a primer combination, a kit and a detection method for simultaneously detecting three echinococcosis pathogens, and belongs to the technical field of parasitic pathogen detection. The primer combination comprises a primer sequence as shown in SEQ ID NO. 1-6. The primer combination comprises a primer sequence as shown in SEQ ID NO. The primer pair combination designed by the invention does not interfere with each other when multiple PCR amplification is carried out in the same system under the same condition, is strong in specificity and high in sensitivity, and is designed for echinococcosis pathogens (echinococcus multilocularis, narrow-sense echinococcus granulosus and echinococcus stone). On the basis, a multiplex PCR method capable of identifying narrow-sense echinococcus granulosus, echinococcus multilocularis and echinococcus stone in faeces and tissues is established, the method is high in specificity and sensitivity, has the advantages of high flux, simplicity, convenience and rapidness, can remarkably improve the working efficiency, reduces the time and economic cost, and is suitable for popularization and application. The method has a wide application prospect in the field of echinococcosis molecular epidemiological investigation.

The invention discloses p38-siRNA and application thereof in treatment of cystic echinococcosis and alveolar echinococcosis, and belongs to the field of biomedicine. The technical problem to be solved by the invention is how to effectively treat alveolar echinococcosis or / and cystic echinococcosis. The p38-siRNA disclosed by the invention is a double-stranded RNA (Ribonucleic Acid) consisting of two single-stranded RNAs as shown in SEQ ID No. 1 and SEQ ID No. 2 in a sequence table. After the p38-siRNA disclosed by the invention is used for interfering with the protoscolex (PSCs), the growth and development of the echinococcus granulosus and the echinococcus multilocularis are obviously inhibited; in-vivo experiments prove that after interference of the p38-siRNA, focuses of the two types of echinococcosis are obviously reduced, fibrosis is weakened, inflammatory cells are reduced, and Treg cells are obviously increased. Therefore, the p38-siRNA provided by the invention can be used for treating the alveolar echinococcosis and the cystic echinococcosis.

The invention discloses application of a histone methyltransferase inhibitor BIX-01294 in preparation of a medicine for treating alveolar echinococcosis, and belongs to the field of biomedicine. The technical problem to be solved by the invention is how to treat and / or prevent alveolar echinococcosis. The invention finds that the BIX-01294 can be used for treating and / or preventing alveolar echinococcosis, has a remarkable killing effect on the protoscolex of echinococcus multilocularis and the vesicle stage in the continuous period in vitro, and can destroy tissue structures such as a head hook, a suction cup, microvillus and the like of the protoscolex so as to cause collapse of the vesicle in the continuous period. In addition, BIX-01294 treatment can inhibit the ability of echinococcus multilocularis protoscolex to develop towards cysts in a mouse secondary infection model body, and the infection rate and the liver transfer rate are both reduced. Therefore, the BIX-01294 can be used as the medicine for treating the alveolar echinococcosis.

The present invention relates to the field of biotechnology, and in particular to primer combinations, reagent combinations, kits, and their applications and methods in identifying Echinococcus granulosus G1 type and Echinococcus multilocularis. The present invention is based on the principle of recombinase polymerase amplification combined with lateral flow chromatography test strips, designs specific primers for the mitochondrial genomes of Echinococcus granulosus G1 type and Echinococcus multilocularis, and achieves accurate identification of Echinococcus granulosus G1 type and Echinococcus multilocularis by optimizing the concentrations of relevant reagents and reaction conditions. The present invention has high sensitivity, strong specificity, high accuracy, and good repeatability. In addition, the entire detection process is convenient and fast, requiring only a constant temperature heating instrument and no other expensive instruments. The present invention greatly shortens the detection time of pathogens and reduces the equipment conditions required for detection, thereby meeting the needs of rapid detection of Echinococcus granulosus G1 type and Echinococcus multilocularis on-site or at grassroots units, and has broad application prospects.

The invention discloses an application of maduramicin ammonium in preparation of a medicine for treating helminthosis. The helminthosis is echinococcosis multilocularis or trichinosis. According to the invention, (1) a blank control group, (2) a DMSO negative control group, (3) an ABZ positive control group, and (4) experimental groups with initial drug concentrations of 50, 80 and 100 [mu] M are respectively set. Respectively observing the forms of insect bodies when the initial effective action time of the medicine is 24, 48 and 72 hours, calculating the death rate, and further performing optimization analysis on the concentration and the effective action time. The result shows that the killing rate of the maduramicin ammonium to the echinococcus multilocularis protoscolex is 100% under the conditions of 24 hours and the concentration of 50 mu M; the killing rate of trichina muscle larvae is 67.83% at the concentration of 50 [mu] M in 72 h; the killing rates of adult trichina and newborn larvae are 93.62% and 99.35% respectively under the conditions of 24 hours and the concentration of 50 [mu] M. The result shows that the maduramicin ammonium has a good killing effect on the echinococcus multilocularis protoscolex and trichina, and can be used as a potential medicine for treating worm diseases.